Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial

Immune checkpoint inhibitors have shown efficacy against metastatic triple-negative breast cancer (mTNBC) but only for PD-L1(positive) disease. The randomized, placebo-controlled ALICE trial (NCT03164993) evaluated the addition of atezolizumab (anti-PD-L1) to immune-stimulating chemotherapy in mTNBC...

Descripción completa

Detalles Bibliográficos
Autores principales: Røssevold, Andreas Hagen, Andresen, Nikolai Kragøe, Bjerre, Christina Annette, Gilje, Bjørnar, Jakobsen, Erik Hugger, Raj, Sunil Xavier, Falk, Ragnhild Sørum, Russnes, Hege Giercksky, Jahr, Thea, Mathiesen, Randi Ruud, Lømo, Jon, Garred, Øystein, Chauhan, Sudhir Kumar, Lereim, Ragnhild Reehorst, Dunn, Claire, Naume, Bjørn, Kyte, Jon Amund
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800277/
https://www.ncbi.nlm.nih.gov/pubmed/36482103
http://dx.doi.org/10.1038/s41591-022-02126-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800277/
https://www.ncbi.nlm.nih.gov/pubmed/36482103
http://dx.doi.org/10.1038/s41591-022-02126-1

Ejemplares similares